(NASDAQ: ARDX) Ardelyx's forecast annual revenue growth rate of 66.03% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.96%, and it is also forecast to beat the US market's average forecast revenue growth rate of 10.23%.
Ardelyx's revenue in 2024 is $124,456,000.On average, 6 Wall Street analysts forecast ARDX's revenue for 2024 to be $48,188,806,885, with the lowest ARDX revenue forecast at $42,911,953,595, and the highest ARDX revenue forecast at $54,034,344,778. On average, 6 Wall Street analysts forecast ARDX's revenue for 2025 to be $85,731,996,218, with the lowest ARDX revenue forecast at $73,994,150,544, and the highest ARDX revenue forecast at $99,063,741,046.
In 2026, ARDX is forecast to generate $134,771,735,834 in revenue, with the lowest revenue forecast at $121,057,222,522 and the highest revenue forecast at $148,546,747,507.